Julian D Gillmore
Overview
Explore the profile of Julian D Gillmore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
273
Citations
9305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Judge D, Alexander K, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al.
J Am Coll Cardiol
. 2025 Mar;
85(10):1003-1014.
PMID: 40074465
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a...
2.
Allinovi M, Trivioli G, Gaudio C, LImperio V, Rauf M, Gillmore J
Nephrol Dial Transplant
. 2025 Mar;
PMID: 40036358
Kidney amyloidosis encompasses a spectrum of heterogeneous conditions in which damage is caused by the deposition of various misfolded proteins that aggregate into fibrils. The main form of renal amyloidosis...
3.
Fontana M, Maurer M, Gillmore J, Bender S, Jay P, Solomon S
J Am Coll Cardiol
. 2025 Jan;
85(7):744-752.
PMID: 39846936
Background: Outpatient worsening heart failure (HF), defined by initiation or intensification of diuretics, is adversely prognostic for patients with either reduced or preserved ejection fraction. Objectives: This study sought to...
4.
Porcari A, Razvi Y, Cappelli F, Nitsche C, Serenelli M, Longhi S, et al.
JAMA Cardiol
. 2025 Jan;
PMID: 39841451
Importance: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid infiltration. Objective:...
5.
Pinney J, Roufosse C, Kousios A, Chaidos A, Gillmore J, Rainone F, et al.
Br J Haematol
. 2025 Jan;
206(2):447-463.
PMID: 39777620
This guideline provides consensus opinion on the investigations required for people presenting with suspected monoclonal gammopathy of renal significance to both nephrology and haematology physicians. The guideline discusses the principles...
6.
Raheja S, Verona G, Florent P, Rendell N, Nocerino P, Ellemerich S, et al.
Amyloid
. 2024 Dec;
32(1):46-53.
PMID: 39676281
Background: Proteomics is routinely used to type clinical amyloid deposits, and offers additional benefit of identifying genetic variants, which can be diagnostically useful. Reviewing the proteomics data for ATTR patients...
7.
Fontana M, Maurer M, Gillmore J, Bender S, Aldinc E, Eraly S, et al.
J Am Coll Cardiol
. 2024 Nov;
85(7):753-761.
PMID: 39566871
Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart. Because disease progression is common, practical and sensitive methods...
8.
Judge D, Gillmore J, Alexander K, Ambardekar A, Cappelli F, Fontana M, et al.
Circulation
. 2024 Nov;
151(9):601-611.
PMID: 39556242
Background: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary...
9.
Fontana M, Solomon S, Kachadourian J, Walsh L, Rocha R, Lebwohl D, et al.
N Engl J Med
. 2024 Nov;
391(23):2231-2241.
PMID: 39555828
Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated...
10.
Wixner J, Berk J, Adams D, Polydefkis M, Conceicao I, Attarian S, et al.
Amyloid
. 2024 Nov;
32(1):29-38.
PMID: 39552152
Background: The NEURO-TTRansform trial showed that after 66 weeks of treatment, eplontersen significantly reduced neuropathic impairment and improved quality of life (QoL) in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy...